AFFiRiS AG Strengthens its Development Pipeline With the Foundation of a Christian-Doppler-Laboratory
industrial Partner of the newly-established Christian-Doppler-Laboratory for
Cardiometabolic Immunotherapy. In partnership with the Medical University of
vaccination therapy against Type 2 Diabetes and cardiovascular diseases. The
reason for AFFiRiS’ commitment is its decision to establish an additional top
priority field. In this way, the company’s versatile AFFITOME(R)-technology
will also be applied for the development of vaccines against cardiometabolic
diseases.
Today AFFiRiS AG announced its role as industrial partner in the
newly-established Christian-Doppler-Laboratory for Cardiometabolic
Immunotherapy at the Medical University of
Stulnig
the Christian-Doppler-Laboratory (CD-Laboratory) will work on chronic
inflammatory processes of adipose tissue and of the cardio-vascular system
and thereby contribute to the basic research for a vaccination therapy
against Type 2 Diabetes mellitus and cardio-vascular diseases. The initial
plan for the CD-Laboratory is for seven years and is financed by public
funding and AFFiRiS as an investor.
Additionally, AFFiRiS provides the CD-Laboratory with its proprietary
AFFITOME(R)-technology, which allows the development of highly specific
therapeutic vaccines and is the basis for all previous achievements of
AFFiRiS in the development of vaccinations. These have to date focused mainly
on neurodegenerative diseases. The collaboration with the CD-Laboratory now
implements a new field of attention: Vaccines against inflammatory diseases.
CEO and co-founder of AFFiRiS,
processes are more and more identified as a contributory cause of many
chronic diseases. Taking this into account, we are now investing in the basic
research of the corresponding pathophysiological principles, so that our
technology can contribute to combating inflammatory-induced chronic diseases.
This perfectly fits with our strategy of sustainable diversification and risk
spreading.”
The CD-Laboratory will initially focus its activities on the evaluation
of relevant target structures with functions in the immune system and
inflammatory processes. These same structures will be investigated and
characterized within the framework of the CD-Laboratory.
Head of the Immunology Department at AFFiRiS, adds: “There is increasing
evidence that some of the body’s own structures are involved into the cause
of inflammatory reactions of the adipose tissue. As a consequence, these
reactions contribute to the emergence of Type 2 Diabetes and cardio-vascular
diseases in a way that’s still not fully understood. The underlying
fundamental inflammatory mechanisms will now be investigated at the
CD-Laboratory. It will also be explored, whether and how an active
immunization approach based on our AFFITOME(R)-platform-technology can unfold
its therapeutic efficacy/impact.”
relevance of an investor in a CD-Laboratory: “Investments in the basic
research of a disease are important for the sustainable generation of
innovative therapies – for nations as well as for companies. Programs like
that of the CD-Laboratory in which the Republic of
investor both contribute to the funding together, are therefore
future-oriented and contribute significantly to the appeal of
business and industry location, allowing the growth of research-intensive
companies like AFFiRiS AG.”
About AFFiRiS AG (date
On the basis of the company’s own patent positions AFFiRiS develops
tailor-made peptide vaccines for Alzheimer’s disease, Atherosclerosis,
Parkinson’s disease, Hypertension and several other conditions with unmet
medical need and attractive market sizes. Alzheimer’s is the current lead
indication. For the Alzheimer’s vaccine program, a license and option
agreement with GlaxoSmithKline was closed in
upfront payment of
milestone-dependent) payments of up to
payment of
million
staff at the Campus Vienna Biocenter in
http://www.affiris.com).
Contact AFFiRiS AG:
Julia Bock
Karl-Farkas-Gasse 22
1030 Vienna, Austria
T +43-1-798-15-75 - 303
E julia.bock@affiris.com
W http://www.affiris.com
Editing & Distribution:
PR&D - Public Relations for
Research & Development
Mariannengasse 8
1090 Vienna, Austria
T +43-1-505-70-44
E contact@prd.at
W http://www.prd.at
SOURCE AFFiRiS AG